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Background and purpose — Muscle atrophy is seen in patients 
with metal-on-metal (MOM) hip implants, probably because of 
inflammatory destruction of the musculo-tendon junction. How-
ever, like pseudotumors, it is unclear when atrophy occurs and 
whether it progresses with time. Our objective was to determine 
whether muscle atrophy associated with MOM hip implants pro-
gresses with time.
Patients and methods — We retrospectively reviewed 74 hips 
in 56 patients (32 of them women) using serial MRI. Median age 
was 59 (23–83) years. The median time post-implantation was 83 
(35–142) months, and the median interval between scans was 11 
months. Hip muscles were scored using the Pfirrmann system. 
The mean scores for muscle atrophy were compared between the 
first and second MRI scans. Blood cobalt and chromium concen-
trations were determined.
Results — The median blood cobalt was 6.84 (0.24–90) ppb 
and median chromium level was 4.42 (0.20–45) ppb. The median 
Oxford hip score was 34 (5–48). The change in the gluteus mini-
mus mean atrophy score between first and second MRI was 0.12 
(p = 0.002). Mean change in the gluteus medius posterior portion 
(unaffected by surgical approach) was 0.08 (p = 0.01) and mean 
change in the inferior portion was 0.10 (p = 0.05). Mean pseudo-
tumor grade increased by 0.18 (p = 0.02).
Interpretation — Worsening muscle atrophy and worsening 
pseudotumor grade occur over a 1-year period in a substantial 
proportion of patients with MOM hip implants. Serial MRI helps 
to identify those patients who are at risk of developing worsen-
ing soft-tissue pathology. These patients should be considered for 
revision surgery before irreversible muscle destruction occurs.

MRI is useful in following up patients with metal-on-metal 
(MOM) hip implants because it identifies soft-tissue abnor-
malities. Muscle atrophy forms part of the exaggerated 
inflammatory response to metal wear debris, and it is thought 
to reduce function (Pandit et al. 2008). Other abnormalities 
include abductor tendon avulsion, pseudotumor, peripros-
thetic fluid collections, and synovial thickening (Toms et al. 
2008, Sabah et al. 2011, Hayter et al. 2012, Hart 2013).  
The UK Medicines and Healthcare Products Regulatory 
Agency (MHRA), the European consensus report, and the US 
Food and Drugs Administration (FDA) all recommend cross-
sectional imaging (MRI) of patients with MOM hip implants. 
These agencies also recommend that patients should be fol-
lowed up for the life of the implant. However, it is currently 
unclear how to interpret MRI findings of muscle atrophy.  
The outcome after revision surgery of a MOM hip is worse 
than that after revision of a non-MOM hip because of the soft-
tissue destruction. It may be possible to improve the outcome 
through early investigation and management of patients who 
are at risk of soft-tissue destruction. Several studies have found 
muscle atrophy prevalence ranging from 22% to 90% (Toms et 
al. 2008, Sabah et al. 2011, Hayter et al. 2012). Pseudotumors 
are also believed to cause local destruction, and their preva-
lence can range from 0.1% to 69% (Pandit et al. 2008, Cana-
dian Hip Resurfacing Study 2011, Sabah et al. 2011, Chang et 
al. 2012, Hart et al. 2012).
The wide-ranging prevalence of soft-tissue abnormality is 
believed to be due in part to the variable response of soft tis-
sues to MOM hips, but also to the effect of time. Understand-
ing whether muscle atrophy can progress with time will help 
to identify patients who need repeat MRI, revision surgery, 
or intensive monitoring. Recent studies have assessed the 
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serial progression of soft-tissue pathology, but they have con-
centrated on pseudotumor progression (Almousa et al. 2013, 
Ebreo et al. 2013, van der Weegen et al. 2013). There have 
been no studies assessing changes in muscle atrophy after 
MOM hip arthroplasty using MRI analysis. 
Our aim was to improve the interpretation of muscle changes 
seen in MOM hips by MRI. Our hypothesis was that muscle 
atrophy would not show progression in MRI results taken at 2 
different times.
Methods
We designed a cohort study to examine any change in MRI 
findings over time. We retrospectively reviewed patients 
from our database of patients with MOM hip implants who 
had been discussed at our tertiary referral center. We oper-
ate a multi-disciplinary team (MDT) meeting consisting of 
an expert panel of hip revision surgeons and musculoskeletal 
radiologists who meet on a weekly basis to discuss the man-
agement of patients with MOM hip implants. We selected 
those patients who fulfilled our inclusion criteria (Figure 1).
All patients with 2 available metal artifact reduction sequence 
(MARS) MRI scans without any previous or intervening revi-
sion surgery were considered. 74 hips in 56 patients fulfilled 
the inclusion criteria and were included in the study. These 
included hips of several current-generation designs, including 
total hip arthroplasty and hip resurfacing types (Table 1, see 
Supplementary data).
The median age was 59 (23–83) years and 32 patients were 
women. 46 hip resurfacings and 28 modular stemmed pros-
theses constituted the cohort. 51 hips had been implanted 
using a posterior surgical approach to the hip, 21 hips via a 
lateral approach, and the approach was unknown in 2 cases 
(performed overseas). We re-examined 128 MRI scans of the 
74 hips. The median time since implantation was 83 (35–142) 
months. Clinical details of the patients were also collected, 
including age, sex, blood cobalt levels, blood chromium 
levels, and Oxford hip score. 
The reasons for repeat MRI scanning included monitoring 
of a pseudotumor in an asymptomatic patient (n = 12), moni-
toring of muscle atrophy in an asymptomatic patient (n = 2), 
high ion levels in an asymptomatic patient (n = 3), high ion 
levels and pseudotumor in an asymptomatic patient (n = 7), 
increasing symptoms (n = 39), and increasing symptoms in 
the presence of high metal ion levels (n = 11).
MRI scans were obtained using the MARS protocol (Table 
2). A senior musculoskeletal radiologist (MK), with experi-
ence in reporting MARS MRI scans on patients with MOM 
hip implants, reported all scans. The reader was blind to 
the clinical symptoms of the patient and reported the scans 
randomly without referring to the first scan. The scans were 
then interpreted in consensus between the radiologist and the 
senior surgeons (JS and AH) during the multi-disciplinary 
team meeting. Cohen’s kappa was run to determine whether 
there was agreement between our 2 radiologists (one of them 
MK), who both regularly dual-report MRI scans and present 
their findings to our multi-disciplinary meeting. There was 
moderate agreement (κ = 0.463; p < 0.001) using Landis and 
Koch criteria (Landis and Koch 1977).
Muscle atrophy was defined as a decrease in volume and 
appearance of fatty change according to the grading system 
proposed by Pfirrmann et al. (2005). Grade 0–4 was allocated 
to the illiopsoas, gluteus minimus, gluteus medius (divided 
into anterior, middle, posterior, and inferior portions), and 
gluteus maximus individually (Figure 2).  Muscle tendon 
disruption was reported where there was discontinuity of the 
muscle attachment, and it was described as being either partial 
or complete.
Figure 1.  The study methods, inclusion/exclusion criteria, and study 
outcomes.
MOM hip implant
Statistical analysis
Exclusion:
– no serial imaging available
– poor quality MRI scan
– intervening revision surgery
Study inclusion criteria:
– LD (≥ 36 mm) MOM hip implant
– in situ for > 1 year
– ≥ 2 MARS MRI scans
– no intervening revision surgery
MRIs reported by MSK radiologist:
– muscle atrophy (Pfirrmann score)
– comment on other soft tissues
   including prseudotumor (Hart score)
Outcome 1:
Change in 
muscle atrophy 
grade
Outcome 2:
Correlation of 
atrophy with
other factors
table 2. MARs MRI protocol
Sequences TE (ms) TR (ms) TSE factor BW (Hz)
Axial T1W 18 650 5 446.4
Axial T2W 70 3,972 8 505.1
Coronal T1W 18 650 5 537.6
Coronal STIR 30 3,269 20 847.5
TE: echo time; TR: repetition time; TSE: turbo-spin echo; 
BW: bandwidth; T1W: T1-weighted; T2W: T2-weighted; 
STIR: short tau inversion recovery sequence.
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Other soft-tissue abnormalities were reported if present. 
These included collections of bursal fluid, tendon injuries, and 
presence of pseudotumor.
Pseudotumor presence and grade was defined according to 
a previously published classification (Hart et al. 2012). Pseu-
dotumor volume was measured electronically in all 3 dimen-
sions. The formula for an elliptical volume was used: volume 
(V, cm3) = height (H) × width (W) × depth (D) × 0.52. If more 
than one pseudotumor was present, the combined volume was 
used for the analysis.
Statistics 
Demographics variables are reported as mean (range) and 
outcome variables as mean (SD). All statistical analyses were 
performed using SPSS version 21. Significance was assumed 
with p-values ≤ 0.05.  
1. Change in muscle atrophy over time. 
 a. Muscle scores for each muscle section were considered 
separately.
 b. Paired-samples t-tests were used to compare the change 
in muscle atrophy grade for each named muscle indi-
vidually between the first and second MRI scans.
2. Change in other soft-tissue abnormalities over time.
 a. Paired-samples t-tests were used to compare change in 
presence of bursal fluid collection, presence of tendon 
injury, presence of pseudotumor, grade of pseudotu-
mor, and size of pseudotumor between the first and 
second MRI scans.
3. Analysis to assess for interclass correlation, on the basis 
that patients with bilateral hip implants were included in 
the cohort.
4. Interaction with demographic factors including age, sex, 
blood cobalt levels, blood chromium levels, and Oxford 
hip score was undertaken using an ANOVA analysis.
 a. Demographics (except implant type and sex) were cat-
egorized for the purposes of these analyses, as follows:
  i. Implant type: resurfacing vs. modular THR.
  ii. Age: < 60 or ≥ 60 years.
  iii. Male vs. female.
  iv. Cobalt ppb: < 7 or ≥ 7 (as per MHRA threshold).
  v. Chromium ppb: < 7 or ≥ 7 (as per MHRA thresh-
old).
  vi. Oxford hip score (3 groups): 
   1. Mild symptoms, ≥ 42.
   2. Moderate symptoms, 20–41.
   3. Severe symptoms, < 20.
 b. Hypothesis-driven multivariate analysis using 
ANCOVA was undertaken to assess the following 
hypothesis:
  1. Muscle atrophy does progress with age.
  2. Progression of muscle atrophy is not sex-specific.
  3. Muscle atrophy does increase in patients with metal 
(cobalt) ion levels > 7ppb.
  4. Muscle atrophy progresses in those patients with a 
low Oxford hip score.
Ethics
Approval for this study was obtained from the Royal National 
Orthopaedic Hospital NHS institutional review board (R&D 
reg. number: SE.13.030).
Results
The median blood cobalt ion level was 6.8 (0.24–90) ppb and 
the median chromium level was 4.4 (0.20–45) ppb. Median 
Oxford hip score was 34 (5–48) (Table 1, see Supplementary 
data). 10 patients (13 hips) were asymptomatic (OHS > 41), 
and half of them had blood cobalt ion levels greater than the 
7-ppb threshold set by the MHRA. 
Muscle atrophy
Gluteus minimus atrophy was seen in 54 of 74 hips within 
the cohort, where 45 suffered atrophy of grade 2 or above. 
Posterior gluteus medius muscle atrophy was seen in 35 hips, 
where 15 hips had atrophy of grade 2 or above. The results 
were normally distributed.
The mean atrophy scores from time point 1 (first MRI) 
to time point 2 were assessed using paired-samples t-tests. 
The mean atrophy values were seen to increase in all cases 
(Table 3, see Supplementary data). A statistically signifi-
cant difference was seen for gluteus minimus, gluteus 
Figure 2. MRI demonstrating increasing grades of muscle atrophy in 
MOM hip patients. A. Grade 1. B. Grade 2. C. Grade 3. D. Grade 4. 
Areas of significant atrophy are highlighted with arrows.
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medius posterior portion, and also gluteus medius inferior 
portion.  
The change in the mean atrophy score for gluteus mini-
mus was 0.12 (SD 0.3; p = 0.002). Despite an increase in the 
mean atrophy scores for the anterior and middle portions of 
the gluteus minimus muscles, neither of these reached signifi-
cance. With regard to the gluteus medius posterior portion, the 
change in the mean score was 0.08 (SD 0.3; p = 0.01). For the 
inferior portion, a change of 0.10 (SD 0.5; p = 0.05) was seen 
(Table 3, see Supplementary data and Figure 3). Regarding 
the cases with progressive posterior gluteus medius atrophy 
(n = 6), the mean blood chromium ion level was 11 (3.2–25) 
ppb and the mean cobalt ion level was 21 (3.7–51) ppb. The 
median Oxford hip score for these patients was 27 (8–42) out 
of a maximum possible score of 48. Atrophy scores for ilio-
psoas and gluteus maximus were similar (p = 0.2).
Interclass correlation
The cohort consisted of 74 hips in 56 patients. 36 patients had 
1 MOM hip and the remaining 18 had bilateral MOM hips. 
14 of these 18 patients had had their MOM hips implanted at 
different time points. In such cases, the first hip was taken and 
the second one was excluded. For the remaining 4 patients 
who had had both hips implanted at the same time, 1 of the 
2 hips was randomly selected to be included in the analysis 
and the other was excluded. This approach has been advocated 
by Bryant et al. (2006). Analysis of this smaller sample size 
revealed similar results, where a significant increase in the 
mean atrophy of the gluteus minimus —of 0.12 (SD 0.3)—was 
seen (p = 0.007), and there was a change in atrophy of the pos-
terior portion of the gluteus medius of 0.07 (SD 0.3; p = 0.04). 
The remaining muscle portions did not show any statistically 
significant difference.
Furthermore, when controlling for time between implanta-
tion and first MRI and also time between MRI scans, and after 
all duplicates had been excluded (i.e. so that each case with 
bilateral hips was represented only once), no statistically sig-
nificant results were seen. However, this was limited by the 
small sample size and the results are probably inconclusive.
Other soft-tissue abnormality
Increased bursal fluid and tendon disruption was seen over 
time, but this was not statistically significant (Table 4, see 
Supplementary data). Tendon disruption was present in 24 
hips, and a median Oxford hip score of 34 (8–45) was seen 
in this subgroup of patients. 17 disruptions were partial tears 
and the remaining 7 were complete tears. 2 partial tears had 
developed in patients with normal MARS MRI images on 
first scanning —involving the gluteus medius and the iliopsoas 
tendon, respectively.
Of the partial tears, the gluteus medius only was affected 
in 12 patients, the gluteus medius and minimus were affected 
in 4 patients, and the iliopsoas was affected in only 1 patient. 
Complete tendon disruptions involved both the gluteus medius 
and minimus tendons in 5 patients, and they involved the glu-
teus medius only in 2 patients. The median Oxford hip score 
for the partial tear subgroup was 34 (8–43), and that for the 
complete tear subgroup was 34 (8–45).
Interestingly, 6 of the 7 hips with complete tendon disrup-
tion had antero-lateral pseudotumors causing stripping of the 
insertion of the abductor tendon from the greater tuberosity 
(Table 5, see Supplementary data, and Figure 4). 
Figure 3. The change in muscle atrophy scores from first MRI (green) 
to second MRI (blue), where gluteus minimus and posterior and inferior 
gluteus medius had the greatest mean change between time points.
2.01.51.00.50
Mean atrophy score
Iliopsoas
Gluteus minimus
Anterior gluteus medius
Middle gluteus medius
Posterior gluteus medius
Inferior gluteus medius
Gluteus maximus
First MRI
Second MRI
Figure 4. Example of abductor stripping secondary to pseudotumor 
(marked with arrows). A. Axial image. B. Coronal image. A pseudo-
tumor can be seen traversing the posterior hip around the greater 
tuberosity onto its lateral aspect, which is now void of abductor tendon 
insertion.
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Pseudotumor
41 of the 47 hips had a pseudotumor on MRI examination. 
However, of these 41 pseudotumors, 36 were present at the time 
of the first MRI, median 65 (5–131) months after implantation. 
The development of new pseudotumors was seen, but this 
did not reach statistical significance (p = 0.08). The number 
of patients who had multiple pseudotumors in more than one 
location around the hip did increase significantly (p = 0.05). 
The grade of pseudotumors also increased significantly, with a 
mean increase in grade of 0.18 (SD 0.6; p = 0.02). There was 
no significant increase in pseudotumor size over time.
When analyzed individually, 5 hips developed new pseudo-
tumors within the observation period (Figure 5), and 7 hips 
had an increased grade. Progression of all types of pseudo-
tumor grade was seen, with 2 hips changing from type 1 to 
type 2A, 4 hips changing from type 2A to type 2B, and 1 hip 
changing from type 2B to type 3. On the other hand, 2 hips 
regressed in pseudotumor grade, where 1 changed from type 
3 to type 2B, and the other changed from type 2B to type 2A. 
In the 12 hips in which new or progressive pseudotumor 
change was seen, the median time for the change to occur 
(time from implantation to MRI in which the change was 
seen) was 59 (20–104) months. The median time to develop a 
new pseudotumor was 59 (42–79) months. Median and mean 
blood chromium in these patients was 6.6 ppb, and for cobalt 
these values were 6.2 and 7.2 ppb, respectively. Similarly, the 
median and mean OHS values in these patients were 30 and 
29, respectively.
Interaction with patient factors
The changes over time were assessed to determine whether 
an association existed with implant type, patient age and sex, 
blood cobalt and chromium levels, and patients’ clinical func-
tion scores (Oxford hip score; Table 6, see Supplementary 
data).
The increased atrophy seen at the inferior portion of gluteus 
medius was statistically significantly associated with implant 
type. Patients with a resurfacing implant were more likely to 
have increasing atrophy of the inferior portion of the medius 
muscle (p = 0.04).
Age less than 60 years contributed to increasing atrophy 
of the gluteus minimus (p = 0.02). Gender contributed to 
increased progression of atrophy of the middle portion of the 
gluteus medius, as male patients had a significant associa-
tion (p = 0.02). However, the implications of this finding are 
unclear. 
No statistically significant relationships were found between 
blood cobalt levels, blood chromium levels, or patient function 
on the one hand and changes in muscle atrophy on the other. 
Multivariate analysis using hypothesis-driven ANCOVA 
analysis revealed similar findings to the above. Atrophy of the 
gluteus minimus increased with age (p = 0.002) and atrophy of 
the middle portion of the gluteus medius was more common in 
female patients (p = 0.022).  No correlation between surgical 
approach, blood metal ion levels, and Oxford hip score was 
seen with progressive muscle atrophy. 
Discussion
Our study is limited by the retrospective review of data, where 
time intervals between scans were not standardized, but this 
was factored into our statistical analysis. Secondly, there was 
an element of selection bias since patients were recruited from 
a MOM hip multi-disciplinary team meeting held in our ter-
tiary center, to which patients are referred for second opinions. 
Thus, our findings may not be representative of the whole 
MOM hip population. However, they are likely to be relevant 
to those patients for whom management decisions are most 
difficult. A further limitation of the present study is the knowl-
edge that muscle atrophy can be associated with joint pathol-
ogy such as osteoarthritis (Grimaldi et al. 2009), the degree 
of which is unknown in our group of patients due to the lack 
of protocol for preoperative MRI scanning. Lastly, our study 
may have been limited by its small sample size since further 
analysis after removing bilateral hips failed to show the same 
statistical significance for progressive muscle changes.
Figure 5. Example of new pseudotumor formation (arrows) in a patient 
with bilateral Birmingham hip resurfacing. T2-weighted MRI images. 
Date of implantation was January 2007, time from operation to first 
MRI (panel A) was 69 months, and time from operation to second MRI 
(panel B) was 84 months.
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MARS MRI has been optimized for viewing of the soft tis-
sues surrounding metal hip implants. Despite some remaining 
artifacts, it enables excellent differentiation of soft and hard 
tissues (Nawabi et al. 2014). Our experience supports the use 
of MARS MRI for the assessment of soft-tissue pathology, in 
line with MHRA and FDA recommendations.
It is clear from the present study that muscle atrophy is 
common in patients with MOM hip implants, as three-quar-
ters of the hips had gluteus minimus atrophy and half of them 
had posterior gluteus medius atrophy. We found an increase 
in atrophy of the posterior and inferior portions of the gluteus 
medius, and also of the gluteus minimus over time. 11 of 74 
hips had an increase in gluteus minimus atrophy, and 6 of 74 
hips had an increase in posterior gluteus medius atrophy. We 
found that the patients with progressive posterior-portion atro-
phy were more likely to be female and to have metal ion levels 
greater than 7 ppb. Gender also had an effect on progressive 
atrophy of the middle portion of the gluteus medius, but con-
sidering the group as a whole, progressive atrophy of this 
portion of the gluteus medius was not statistically significant. 
This may have been due to an insufficient sample size, since 
the patient-specific factors that have an effect on MOM hips 
and muscle atrophy are not clearly defined in the literature.
Various research groups have reported the presence of 
muscle atrophy around MOM hips (Toms et al. 2008, Hayter 
et al. 2012, Hart 2013). Toms et al. (2008) found gluteus 
medius atrophy in 8 of 20 symptomatic hips, and gluteus 
minimus atrophy in 9. It is believed that such atrophy may 
follow on from the use of transgluteal surgical approaches 
(Madsen et al. 2004), but the presence of gluteal atrophy in 
patients treated through a posterior approach suggests that this 
is related to the metal-based disease process (Hart 2013). This 
is not to say that muscle atrophy is never seen in conventional 
THA patients (Pfirrmann et al. 2005), but there have not been 
any studies showing progression of muscle atrophy in such 
patients. 
We identified stripping of the abductor tendon (gluteus 
medius and minimus) from its insertion, secondary to a pseu-
dotumor, in 6 hips. Tendon avulsion after hip arthroplasty is 
a recognized complication (Drexler et al. 2014), although the 
prevalence of this problem is unknown. Fang et al. (2008) pre-
viously suggested that periarticular inflammatory collections 
develop along the path of least resistance, which in the native 
hip would include the iliopsoas bursa and laterally into the tro-
chanteric bursa. The surgical approach could possibly intro-
duce spaces, which might explain why pseudotumors are often 
located in various positions around a MOM hip, including 
posteriorly. Furthermore, tendon avulsion has been reported 
in hips following hip arthroplasty—implanted through antero-
lateral and transgluteal approaches (Pfirrmann et al. 2005, 
Toms et al. 2008). In our series, however, we saw abductor 
tendon stripping from both the anterolateral approach and the 
posterior approach, close to lateral pseudotumors—with a dis-
similar appearance to bursal fluid collections by virtue of thick 
irregular walls and mixed internal signal intensity—surround-
ing the greater trochanter and stripping the abductor muscle 
tendons from their insertion (Figures 4 and 5).
Half of our patients’ hips had a pseudotumor on MRI exam-
ination. Pseudotumors are well described in patients with 
MOM hip implants. The reported prevalence in both symp-
tomatic and asymptomatic patients ranges from 0.1% to 69% 
(Pandit et al. 2008, Canadian Hip Resurfacing Study 2011, 
Sabah et al. 2011, Chang et al. 2012, Hart et al. 2012). 
We found progression of pseudotumor grade. In addition, 5 
cases developed new pseudotumors, at a median time point of 
59 months post-implantation. 
Revision of MOM hip implants with soft-tissue pathology 
is associated with poor outcomes, and there is growing evi-
dence to support early revision to a non-MOM hip implant to 
prevent irreversible damage (Daniel et al. 2012). Campbell et 
al. (2008) observed that patients can expect a good outcome if 
their soft tissue remains intact. Grammatopolous et al. (2009) 
reported poor outcomes in patients following revision of a 
MOM hip replacement due to pseudotumor, with a high rate 
of complications. Liddle et al. (2013) highlighted the degree of 
misdiagnosis possible when planning for revision of MOM hip 
implants. They stated that preoperative imaging can underes-
timate the degree of soft-tissue abnormalities seen at revision 
surgery, including a high rate of severe abductor muscle atro-
phy and stripping of the tendinous attachment. If progressive 
and destructive change in soft tissue is possible, prediction of 
those patients who are likely to fail is paramount so that revi-
sion can be undertaken early to ensure a better outcome.
To our knowledge, this is the first study to use serial MRI 
imaging to assess the longitudinal changes in muscle atrophy 
associated with large-diameter MOM hip implants. Recent 
studies concentrating on the natural history of soft-tissue 
pathology have focused on pseudotumors, and since most 
authors have used the Anderson classification (Anderson et al. 
2011) when grading MRI findings, it is difficult to quantify 
the effect on muscles and other soft-tissue abnormalities indi-
vidually. 
Almousa et al. (2013) used serial ultrasound assessments (2 
years apart), and demonstrated variation in the size of pseudo-
tumors—especially after revision surgery. Ebreo et al. (2013) 
used serial MRI to classify soft-tissue changes in 80 patients 
with 28-mm MOM Ultima hips. 6 hips with normal scans 
developed disease after sequential scanning, and overall, 15 
hips showed progression on serial imaging. We are not sure if 
these findings can be generalized to large diameter (LD, > 36 
mm) MOM hips, since the mode of failure of the Ultima stem 
includes macroscopic corrosion of the stem-cement interface 
(Donell et al. 2010), which is not seen with other LD MOM 
hips. Van der Weegen et al. (2013) reported serial MRI find-
ings in 37 hips with change in only 2 cases, including a new 
pseudotumor that developed 4 years after implantation.
36 of the 41 pseudotumors identified in our study were pres-
ent at the time of the first MRI, median 65 months after sur-
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gery. This is similar to the results of other studies, which sug-
gests that most pseudotumors arise within 5 years of implanta-
tion (Ebreo et al. 2013, van der Weegen et al. 2013) and reach 
a steady state.  
Conclusion
Muscle atrophy after MOM hip arthroplasty is a common find-
ing. This is the first study involving serial MRI of large-diame-
ter MOM hips to investigate hip muscle scores. In 6 of 74 hips 
studied, we found that atrophy of the posterior third of the 
gluteus medius progressed between scans with a mean interval 
of 11 months. Assessment of the muscles on MRI is important 
in the monitoring of these patients, in order to help identify 
those who are at risk of developing abductor dysfunction and 
poor clinical outcome. An interval of 12 months would be rea-
sonable, based on our observations. MRI findings are likely 
to precede clinical symptoms and support repeat MRI in the 
follow-up of a MOM hip.
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